Fluorinov Pharma, FACIT And OICR Announce Novel Candidate Drugs Modulating NaV 1.8, NaV 1.7 Sodium Channels For The Safer Treatment Of Cancer Pain And Brain Cancer-Related Epilepsy
4/25/2014 7:53:34 AM
TORONTO--(BUSINESS WIRE)--Fluorinov Pharma, an emerging Ontario-based drug development company, has developed three structurally distinct candidate drugs that selectively target pain-specific nerve sodium channels (Nav 1.8 and Nav 1.7), intended to treat cancer pain and brain cancer-related epilepsy, announced Malik Slassi, PhD, Chief Scientific Officer. The candidate drugs have shown an excellent preliminary safety profile, improved treatment of pain and epilepsy and are expected to have fewer sedative side effects compared to the current standard of treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by